Mandate

Vinge advises Adelis and other shareholders in connection with the sale of Logent

May 24, 2019 M&A

Vinge advises Adelis and other shareholders in connection with the sale of Logent to Stirling Square Capital Partners.

Logent is an independent contract logistics partner to logistics-intensive companies in Sweden and Norway. Logent has approximately 3,000 employees and operates along the whole logistics value chain within the business areas Warehousing, Transport Management, Customs, Ports, Staffing & Recruitment and Consulting.

Closing of the transaction is subject to the Swedish Competition Authority's approval. 

Vinge’s team consisted of partner Christina Kokko together with, among others, associates Samra Baytar, Manne Bergström andTove Lövgren Frisk and VDR Specialist Viktoria Owets. 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026